ACTG Protocol Facilitator

Dr. Peters’ role is to increase awareness of the ACTG as a place to do studies in HBV. She has made formal and informal contacts with nearly every company working in HBV Cure. She will continue to interact with companies studying new HBV drugs by interactions at national and international liver and HIV meetings, including AASLD, CROI, EASL and other focused meetings. She will work with Steering Committee of Hepatitis TSG to identify young investigators who can lead new studies in HBV Cure with seasoned investigators as co-chairs. Two such studies are near to opening (A5368 and A5382). On a twice monthly basis she reports her work to Hep TSG.